Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider James C. Hamilton Sells 32,729 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James C. Hamilton sold 32,729 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now owns 272,122 shares in the company, valued at $5,393,458.04. This represents a 10.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded up $0.17 during midday trading on Tuesday, hitting $19.67. The company’s stock had a trading volume of 1,197,900 shares, compared to its average volume of 1,241,250. The stock has a fifty day moving average price of $21.03 and a 200 day moving average price of $22.56. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -3.92 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a one year low of $17.05 and a one year high of $39.83. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in ARWR. HighTower Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 11.5% in the third quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock valued at $2,401,000 after acquiring an additional 12,706 shares during the period. Avoro Capital Advisors LLC boosted its holdings in Arrowhead Pharmaceuticals by 3.9% in the 2nd quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock valued at $231,022,000 after purchasing an additional 333,333 shares during the period. Intech Investment Management LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at $659,000. Erste Asset Management GmbH purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $924,000. Finally, Millennium Management LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 61.9% in the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after purchasing an additional 202,280 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ARWR. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, December 20th. Finally, Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.